Welcome to our dedicated page for Grace Therapeutics news (Ticker: GRCE), a resource for investors and traders seeking the latest updates and insights on Grace Therapeutics stock.
Grace Therapeutics, Inc. develops specialty biopharmaceutical products led by GTx-104, a clinical-stage injectable formulation of nimodipine for intravenous infusion in patients with aneurysmal subarachnoid hemorrhage, or aSAH. The company’s updates center on the GTx-104 New Drug Application, FDA correspondence, chemistry, manufacturing and controls matters, and clinical data from the STRIVE-ON Phase 3 safety trial.
Recurring news also covers medical-conference presentations, intellectual-property developments for nimodipine parenteral administration, quarterly financial results, corporate presentations, and capital actions such as warrant exercises tied to prior private placements.
Grace Therapeutics (Nasdaq: GRCE) announced a virtual Key Opinion Leader (KOL) event scheduled for November 20, 2024, at 2:00 PM ET. The event will focus on GTx-104, their novel injectable formulation of nimodipine developed for aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening condition.
Featured speakers include Dr. Abhishek Ray from University Hospitals and Dr. Andrew Webb from Massachusetts General Hospital. They will discuss the unmet medical needs and current treatment landscape for aSAH patients. The presentation will be followed by a Q&A session.